The prevention of the hepatotoxic effects produced by intravenous infusion of taurochenodeoxycholic acid (TCDCA) by coinfusion with taurohyodeoxycholic acid (THDCA) was evaluated in bile fistula rats; the hepatoprotective effects of the latter were also compared with those of tauroursodeoxycholic acid (TUDCA). Rats infused with TCDCA at a dose of 8 mol/min/kg showed reduced bile flow and calcium secretion, as well as increased biliary release of alkaline phosphatase (AP) and lactate dehydrogenase (LDH). This was associated with a very low biliary secretion rate of TCDCA (Ϸ1 mol/min/kg). Simultaneous infusion of THDCA or TUDCA at the same dose preserved bile flow and almost totally abolished the pathological leakage of the two enzymes into bile. The effect was slightly more potent for THDCA. The maximum secretion rate of TCDCA increased to the highest value (8 mol/min/kg) when coinfused with either of the two hepatoprotective bile acids (BA), which were efficiently and completely secreted in the bile, without metabolism. Calcium output was also restored and phospholipid (PL) secretion increased with respect to the control saline infusion. This increase was higher in the THDCA study. These data show that THDCA is highly effective in the prevention of hepatotoxicity induced by intravenous infusion of TCDCA by facilitating its biliary secretion and reducing its hepatic residence time; this was associated with selective stimulation of PL biliary secretion. (HEPATOLOGY 1998;27:520-525.)Taurohyodeoxycholic acid (THDCA) is the taurineamidated form of hyodeoxycholic acid, a natural bile acid present in the pig, other animal species, and also in humans. [1][2][3][4] The steroid structure is characterized by the presence of two hydroxy groups, 3␣ and 6␣, the latter of which is equatorial and oriented toward the back of the steroid moiety. As a result, this molecule is less detergent than the other dihydroxy bile acid (BA), such as chenodeoxycholic acid (CDCA) (3␣, 7␣) or its 3␣, 6 dihydroxy epimer. The hydrophobic-hydrophilic balance of THDCA resembles that of tauroursodeoxycholic acid (TUDCA), with which it also shares similar orientation of the 7 hydroxy group with respect to the 6␣ hydroxyl. The physicochemical properties of this molecule are quite similar to those of TUDCA in terms of lipophilicity and critical micellar concentration (CMC). 5,6 Because of its relatively high hydrophilicity, THDCA has been proposed for use as an alternative to ursodeoxycholic acid (UDCA) or TUDCA for the treatment of cholesterol gallstone dissolution. [7][8][9][10] Recent studies have reported its activity as a cholesterol-dissolving agent, both in vitro and in vivo, and this has been attributed to its ability to selectively stimulate biliary phospholipid secretion. 11 Moreover, hyodeoxycholic acid is a secondary BA derived from hyocholic acid by intestinal bacterial 7␣ dehydroxylation, and thus, it is quite stable to intestinal bacteria; this is a potential advantage compared with UDCA that can undergo either 7 dehydroxylation or 7␣...